Your privacy is very important to us. When you visit our website, please agree to the use of all cookies. For more information about personal data processing, please go to Privacy Policy.
About Us
HuidaGene is a global clinical-stage biotechnology company focusing on discovering, engineering, and developing gene editing tools and gene therapies to rewrite the future of genomic medicine. Based in Shanghai and New Jersey, HuidaGene is committed to addressing patients’ needs globally with various therapeutic programs covering ophthalmology, neurology, neuro-myology, otology and neurology. HuidaGene is committed to delivering cutting-edge gene editing tools and providing precise, safe, and effective one-and-done treatments for patients living with life-threatening conditions worldwide by repairing the cause of their disease. We are committed to transforming the future of genome-editing medicine.
Our Mission
&
Vision
Growth Footprint
-
2018
Oct. Incorporation of HuidaGene in Shanghai
Nov. Completion of Angel round of funding
-
2019
Feb. Completion of the R&D lab
Nov. Completion of Series A financing
-
2020
Nov. Completion of CMC Lab (Shanghai Waigaoqiao Free Trade Zone）
Feb. Discovery of CRISPR-Cas13X/Y RNA editing tools
-
2021
May. Completion of Series B financing
Jul. Incorporation of Cholgene Therapeutics Inc.( US subsidiary)
Nov. Discovery of CRISPR-Cas12 DNA editing tools
Dec. Completion of first external licensing partnership with Cas13X/Y RNA editing tools
-
2022
Jan. US patent covering CRISPR-Cas13X/Y RNA editing tools granted by USPTO
May. Completion of Series C financing
Sept. CN patent covering CRISPR-Cas13X RNA base editor granted by CNIPA
-
2023
Jan. IND clearance for the multinational clinical trial of HG004 (HG00402) to treat inherited retinal diseases (IRDs) by the U.S. FDA
Jan. HuidaGene dosed first subject in the HG004 IIT (HG00401) clinical trial for RPE65 mutation-associated IRD
Mar. HG004 granted orphan drug designation by the U.S. FDA
Apr. HuidaGene received IND approval of the first China multi-regional, multi-national master protocol of HG004 (HG00402) by China NMPA
Apr. Discovery of glycosylase-based guanine base editor (gGBE)
May. US patent covering CRISPR-Cas12 DNA editing tools granted by USPTO
May. Discovery of glycosylase-based guanine base editor (gGBE)
Aug. FDA granted Rare Pediatric Disease Designation (RPDD) to HG004
Sep. First patient dosed of the world’s first novel CRISPR/Cas13 RNA-editing therapy,HG202Oct. FDA granted RPDD to HG204 for the treatment of MECP2 Duplication Syndrome
-
2018
-
2019
-
2020
-
2021
-
2022
-
2023